350 Avsnitt

  1. 268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

    Publicerades: 2023-07-27

  2. 267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

    Publicerades: 2023-07-20

  3. 266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

    Publicerades: 2023-07-13

  4. 265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

    Publicerades: 2023-06-29

  5. 264: Messy PBM conflicts, debatable vaccines, & the future of flu season

    Publicerades: 2023-06-22

  6. 263: Biogen's messy board, Laronde's data problem, & the downside of a boom

    Publicerades: 2023-06-15

  7. 262: Merck v. USA, the best of ASCO, and Leqembi at the FDA

    Publicerades: 2023-06-08

  8. 261: Fake medical devices, real cancer drugs, & curious Ozempic effects

    Publicerades: 2023-06-01

  9. 260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA

    Publicerades: 2023-05-25

  10. 259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

    Publicerades: 2023-05-18

  11. 258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

    Publicerades: 2023-05-11

  12. 257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business

    Publicerades: 2023-05-04

  13. 256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval

    Publicerades: 2023-04-27

  14. 255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters

    Publicerades: 2023-04-20

  15. 254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future

    Publicerades: 2023-04-13

  16. 253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

    Publicerades: 2023-04-06

  17. 252: Biotech's monkey shortage, the broken generics market, & conference cancel culture

    Publicerades: 2023-03-30

  18. 251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster

    Publicerades: 2023-03-23

  19. 250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

    Publicerades: 2023-03-16

  20. 249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

    Publicerades: 2023-03-09

5 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site